Cannabinoids

Getty images / skynesher

CBD in 2022: A year in review

By Danielle Masterson

We’re five years in, so what does the CBD industry look like now and what can we expect in 2023? We spoke with several CBD experts who walked us through the highs and lows of 2022.

A growing number of firms are using genetically engineered yeast to biosynthesize cannabinoids by effectively reverse engineering how Cannabis sativa plants make these molecules (picture: Demetrix)

Demetrix begins demo scale production of rare cannabinoid CBG

By Elaine Watson

Demetrix – one of a new wave of biotech firms producing cannabinoids via biosynthesis (rather than extracting them from cannabis plants) – has commenced 15,000-liter demo-scale fermentation production of CBG (cannabigerol), the first rare cannabinoid...

Spotlight

Follow us

Expertise Hub

Products

View more

Webinars

Featured Suppliers

All